DHDelia Hoffmann

Delia Hoffmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Delia Hoffmann has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 3D Histological Analysis of Soft Tissues by Contrast-Enhanced X-Ray Microfocus Computed Tomography: Screening and Staining Optimization of Contrast-Enhancing Staining Agents

    by Delia Hoffmann, Tim Balcaen, Sarah Vangrunderbeeck, Léna Puigdevall Mata, Arne Maes, Grzegorz Pyka, Laure Dumoutier, Catherine Behets, Wim De Borggraeve, Greet Kerckhofs

    The gold standard for studying biological soft tissues at the microscale (i.e., histology) is tissue sectioning with subsequent colorimetric or fluorescent staining and visual inspection under the microscope. When tissue integrity must be maintained for 3D histological assessment, contrast-enhanced microfocus X-ray computed tomography (CECT) is a promising solution, but there is still a lack of staining protocol optimization of contrast-enhancing staining agents (CESAs). Therefore, in this study, mouse auricles were incubated with Hafnium-substituted Wells–Dawson polyoxometalate, cationic iodinated contrast agent, or Lugol's iodine and were imaged with high-resolution CECT. Alignment with corresponding H&E-stained sections enabled the identification and segmentation of different tissue types. Contrast differences between tissue types were increased by washing the samples after staining or by combining CESAs. Finally, we proved that the latter could be used to quantitatively assess the 3D thickness distribution of the epidermis in the ears of a mouse model of psoriasis-like dermatitis. In conclusion, CECT and bright-field microscopy are complementary and not mutually exclusive techniques for the histological assessment of biological tissues. While bright-field microscopy gives detailed information about the cellular composition of tissues, CECT provides a better insight into the spatial interrelationship of tissues and is a powerful tool for performing 3D structural quantification.


  • Open Access

    Supplementary Table 1 and Supplementary Figures 1-5 from Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers

    by Delia Hoffmann, Tereza Dvorakova, Vincent Stroobant, Caroline Bouzin, Aurélie Daumerie, Marie Solvay, Simon Klaessens, Marie-Claire Letellier, Jean-Christophe Renauld, Nicolas van Baren, et al.

    Supplementary figures and tables

  • Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase

    by Simon Klaessens, Vincent Stroobant, Delia Hoffmann, Mads Gyrd-Hansen, Luc Pilotte, Nathalie Vigneron, Etienne De Plaen, Benoit J. Van Den Eynde

    Significance: Besides being a protein building block, the essential amino acid tryptophan is a neurotransmitter precursor and a potent immunomodulator. Therefore, its systemic concentration needs to be constant in spite of irregular dietary supply. How this is achieved is unclear. Dietary tryptophan is degraded in the liver by tryptophan 2,3-dioxygenase (TDO). We report that tryptophan itself regulates TDO stability: Abundant tryptophan binds to noncatalytic exosites and stabilizes active tetrameric TDO. Hence, tryptophan is rapidly degraded and tryptophanemia contained. When tryptophan is scarce, it detaches from exosites, inducing tetramer dissociation and unmasking a degron triggering TDO polyubiquitination and proteasome-mediated degradation. Tryptophan catabolism is interrupted and blood level maintained. Matching catabolism to dietary supply, this mechanism ensures rapid and tight control of tryptophanemia.


  • Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors

    by Florence Schramme, Stefano Crosignani, Kim Frederix, Delia Hoffmann, Luc Pilotte, Vincent Stroobant, Julie Preillon, Gregory Driessens, Benoit J. Van Den Eynde

    Tryptophan 2,3-dioxygenase (TDO) is an enzyme that degrades tryptophan into kynurenine and thereby induces immunosuppression. Like indoleamine 2,3-dioxygenase (IDO1), TDO is considered as a relevant drug target to improve the efficacy of cancer immunotherapy. However, its role in various immunotherapy settings has not been fully characterized. Here, we described a new small-molecule inhibitor of TDO that can modulate kynurenine and tryptophan in plasma, liver, and tumor tissue upon oral administration. We showed that this compound improved the ability of anti-CTLA4 to induce rejection of CT26 tumors expressing TDO. To better characterize TDO as a therapeutic target, we used TDO-KO mice and found that anti-CTLA4 or anti-PD1 induced rejection of MC38 tumors in TDO-KO, but not in wild-type mice. As MC38 tumors did not express TDO, we related this result to the high systemic tryptophan levels in TDO-KO mice, which lack the hepatic TDO needed to contain blood tryptophan. The antitumor effectiveness of anti-PD1 was abolished in TDO-KO mice fed on a tryptophan-low diet that normalized their blood tryptophan level. MC38 tumors expressed IDO1, which could have limited the efficacy of anti-PD1 in wild-type mice and could have been overcome in TDO-KO mice due to the high levels of tryptophan. Accordingly, treatment of mice with an IDO1 inhibitor improved the efficacy of anti-PD1 in wild-type, but not in TDO-KO, mice. These results support the clinical development of TDO inhibitors to increase the efficacy of immunotherapy of TDO-expressing tumors and suggest their effectiveness even in the absence of tumoral TDO expression. See article by Hoffmann et al., p. 19


  • Open Access

    Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers

    by Delia Hoffmann, Tereza Dvorakova, Vincent Stroobant, Caroline Bouzin, Aurélie Daumerie, Marie Solvay, Simon Klaessens, Marie-Claire Letellier, Jean-Christophe Renauld, Nicolas van Baren, et al.

    Tryptophan catabolism is used by tumors to resist immune attack. It can be catalyzed by indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO). IDO1 is frequently expressed in tumors and has been widely studied as a potential therapeutic target to reduce resistance to cancer immunotherapy. In contrast, TDO expression in tumors is not well characterized. Several human tumor cell lines constitutively express enzymatically active TDO. In human tumor samples, TDO expression has previously been detected by transcriptomics, but the lack of validated antibodies has precluded detection of the TDO protein and identification of TDO-expressing cells. Here, we developed novel TDO-specific monoclonal antibodies and confirmed by immunohistochemistry the expression of TDO in the majority of human cancers. In all hepatocarcinomas (10/10), TDO was expressed by most tumor cells. Some glioblastomas (10/39) and kidney carcinomas (1/10) also expressed TDO in tumor cells themselves but only in focal tumor areas. In addition, all cancers tested contained foci of nontumoral TDO-expressing cells, which were identified as pericytes by their expression of PDGFRβ and their location in vascular structures. These TDO-expressing pericytes belonged to morphologically abnormal tumor vessels and were found in high-grade tumors in the vicinity of necrotic or hemorrhagic areas, which were characterized by neoangiogenesis. We observed similar TDO-expressing pericytes in inflammatory pulmonary lesions containing granulation tissue, and in chorionic villi, two tissue types that also feature neoangiogenesis. Our results confirm TDO as a relevant immunotherapeutic target in hepatocellular carcinoma and suggest a proangiogenic role of TDO in other cancer types. See article by Schramme et al., p. 32


  • Open Access

    Induction of tryptophan 2,3-dioxygenase expression in human monocytic leukemia/lymphoma cell lines THP-1 and U937

    by Delia Hoffmann, Luc Pilotte, Vincent Stroobant, Benoit J Van Den Eynde

    Tumor-associated macrophages are immune cells with diverse functions in tumor development. Among other functions, they downregulate immune-mediated tumor rejection by depriving lymphocytes of nutrients. The essential amino acid tryptophan is metabolized by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase (TDO). Indoleamine 2,3-dioxygenase 1 is expressed in a large number of human tumors, and inhibitors are in development to improve immunotherapy. Tryptophan 2,3-dioxygenase was also found in human tumors and preclinical working models confirmed its immunosuppressive power. We explored a potential expression of TDO by macrophages. This enzyme could be induced in two human cell lines, THP-1 and U937, by incubation with phorbol myristate acetate, lipopolysaccharide, and interferon gamma. Phorbol-myristate-acetate-mediated induction was inhibited by rottlerin, a protein kinase C inhibitor. In contrast to these monocytic cell lines, other cell lines or fresh human monocytes isolated from peripheral blood mononuclear cells and differentiated into proinflammatory or anti-inflammatory macrophages could not be induced to express TDO. Our results suggest that TDO might play an immunosuppressive role in human monocytic leukemias but not in untransformed macrophages.


  • Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance

    by Marc Hennequart, Luc Pilotte, Stefania Cane, Delia Hoffmann, Vincent Stroobant, Etienne De Plaen, Benoît J. Van Den Eynde

    Tumors use various mechanisms to avoid immune destruction. Cyclooxygenase-2 (COX-2) expression may be a driver of immune suppression in melanoma, but the mechanisms involved remain elusive. Here, we show that COX-2 expression drives constitutive expression of indoleamine 2,3-dioxygenase 1 (IDO1) in human tumor cells. IDO1 is an immunosuppressive enzyme that degrades tryptophan. In a series of seven human tumor lines, constitutive IDO1 expression depends on COX-2 and prostaglandin E2 (PGE2), which, upon autocrine signaling through the EP receptor, activates IDO1 via the PKC and PI3K pathways. COX-2 expression itself depends on the MAPK pathway, which therefore indirectly controls IDO1 expression. Most of these tumors carry PI3K or MAPK oncogenic mutations, which may favor constitutive IDO1 expression. Celecoxib treatment promoted immune rejection of IDO1-expressing human tumor xenografts in immunodeficient mice reconstituted with human allogeneic lymphocytes. This effect was associated with a reduced expression of IDO1 in those ovarian SKOV3 tumors and an increased infiltration of CD3+ and CD8+ cells. Our results highlight the role of COX-2 in constitutive IDO1 expression by human tumors and substantiate the use of COX-2 inhibitors to improve the efficacy of cancer immunotherapy, by reducing constitutive IDO1 expression, which contributes to the lack of T-cell infiltration in “cold” tumors, which fail to respond to immunotherapy. Cancer Immunol Res; 5(8); 695–709. ©2017 AACR.


  • Open Access

    Regulation of Macrophage Motility by the Water Channel Aquaporin-1: Crucial Role of M0/M2 Phenotype Switch

    by Donatienne Tyteca, Tomoya Nishino, Huguette Debaix, Patrick Van Der Smissen, Francisca N'KUli, Delia Hoffmann, Yvette Cnops, Virginie Rabolli, Geert van Loo, Rudi Beyaert, et al.

    The water channel aquaporin-1 (AQP1) promotes migration of many cell types. Although AQP1 is expressed in macrophages, its potential role in macrophage motility, particularly in relation with phenotype polarization, remains unknown. We here addressed these issues in peritoneal macrophages isolated from AQP1-deficient mice, either undifferentiated (M0) or stimulated with LPS to orientate towards pro-inflammatory phenotype (classical macrophage activation; M1). In non-stimulated macrophages, ablation of AQP1 (like inhibition by HgCl2) increased by 2–3 fold spontaneous migration in a Src/PI3K/Rac-dependent manner. This correlated with cell elongation and formation of lamellipodia/ruffles, resulting in membrane lipid and F4/80 recruitment to the leading edge. This indicated that AQP1 normally suppresses migration of resting macrophages, as opposed to other cell types. Resting Aqp1-/- macrophages exhibited CD206 redistribution into ruffles and increased arginase activity like IL4/IL13 (alternative macrophage activation; M2), indicating a M0-M2 shift. In contrast, upon M1 orientation by LPS in vitro or peritoneal inflammation in vivo, migration of Aqp1-/- macrophages was reduced. Taken together, these data indicate that AQP1 oppositely regulates macrophage migration, depending on stimulation or not by LPS, and that macrophage phenotypic and migratory changes may be regulated independently of external cues.